GlassScriptPhysician profile
Doreen Abrigo
NPI 1801361845
$13,981.29
in general payments reported to CMS, 2019-2025
58 companies · $3,047 in 2025
The $3,047 reported for 2025 was more than what 97% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,962 · 2022: $2,460 · 2023: $2,593 · 2024: $2,920 · 2025: $3,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,559.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,720.27 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,371.92 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Otsuka America Pharmaceutical, INC. | $946.33 | 2021-2025 | Rexulti |
| Pfizer INC. | $887.35 | 2021-2025 | |
| Astellas Pharma US INC | $763.24 | 2021-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $751.94 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $625.19 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $588.42 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Amgen INC. | $573.76 | 2021-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $572.71 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $523.06 | 2021-2025 | Xarelto, Spravato |
| Corcept Therapeutics | $514.99 | 2021-2025 | Korlym |
| Noven Therapeutics, LLC | $282.80 | 2023-2025 | Xelstrym |
| Bayer Healthcare Pharmaceuticals INC. | $271.45 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $253.39 | 2021-2024 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doreen Abrigo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.